HEART Pilot Trial Evaluating Spironolactone in Adults with Degenerative Thoracic Aortic Aneurysms

What this Trial Is About

Researchers are evaluating whether spironolactone can reduce aortic stiffness in adults with degenerative thoracic aortic aneurysms. This study compares spironolactone to a placebo to see how it affects the stiffness of the aorta, measured by carotid-femoral pulse wave velocity cfPWV. The trial is a pilot randomized controlled study led by Mayo Clinic and includes adults 18 years and older with specific aortic enlargement. Participants will be randomly assigned to receive either spironolactone or a placebo. The treatment starts with a dose of 25 mg once daily for the first 4 weeks, then increases to 50 mg once daily for an additional 5 months. The study uses triple masking to keep the treatment assignments hidden from participants and researchers. During the study, participants will have their aortic stiffness measured at the start and after 6 months through tests like cfPWV and assessments of blood pressure and arterial compliance. Researchers will track changes in central blood pressure, aortic impedance, and wave reflections. The total treatment period is 6 months, with safety and effectiveness monitored throughout the trial.

HEART: Pilot Randomized Controlled Trial